---
title: "Akeso Announces Trustee Purchase of 200,000 Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305977146.md"
description: "Akeso, Inc. ( (HK:9926) ) just unveiled an announcement.Akeso, Inc. announced that a trustee purchased 200,000 of its shares on the market on November 18, 2026, for approximately HK$12 million. The purchase was funded by the company’s existing available cash resources, and the board said it reflected the company’s confidence in its business outlook and future prospects."
datetime: "2026-11-18T13:08:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305977146.md)
  - [en](https://longbridge.com/en/news/305977146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305977146.md)
generator: "portal-rs"
---

# Akeso Announces Trustee Purchase of 200,000 Shares

Akeso, Inc. ( (HK:9926) ) just unveiled an announcement.

Akeso, Inc. announced that a trustee purchased 200,000 of its shares on the market on November 18, 2026, for approximately HK$12 million. The purchase was funded by the company’s existing available cash resources, and the board said it reflected the company’s confidence in its business outlook and future prospects.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**